Achilles Therapeutics announced the appointment of Professor Sergio Quezada as Chief Scientific Officer (CSO) with effect from 6 April 2020. Achilles was founded in 2016 by lead investor Syncona Ltd. and in September 2019 the Company raised £100 million in an oversubscribed Series B financing led by RA Capital, cornerstoned by Syncona and joined by new investors including Forbion, Invus, Perceptive Advisors and Redmile Group.